Pruritis - Pipeline Insight, 2019 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritis pipeline landscape is provided which includes the disease overview and Pruritis treatment guidelines. The assessment part of the report embraces, in depth Pruritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pruritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pruritus (itching) refers to a sensation of the skin which causes a desire to scratch. Itching is a normal body response to protect us from harmful external substances or parasites such as insect bites. However, pruritus (or itch) is a common and distressing symptom of many skin diseases, systemic illnesses and psychological disorders. Itch is perhaps the commonest presenting symptom of skin disorders. In any two week period, 8-9% of the population suffer from significant pruritus. Pruritus lasting more than 6 weeks is called chronic pruritus. Pruritus may be localised to one area or generalized all over the skin. There are many possible causes, but for some people with pruritus no obvious cause can be found. Generalised pruritus without rash (especially in people over 65 years of age) is most commonly caused by dry skin. It may also be caused by medicines or by internal diseases affecting the body. There remain a small number of individuals with itch and no apparent underlying cause or rash. This is more common in the elderly.
Pruritis Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Pruritis targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Pruritis pipeline report covers 7+ companies. Some of the key players include Nippon Shinyaku (NST 141), GlaxoSmithKline (Linerixibat) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Pruritis Analytical Perspective by DelveInsight
• In-depth Pruritis Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Pruritis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Pruritis report provides an overview of therapeutic pipeline activity for Pruritis across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Pruritis therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Pruritis Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Pruritis
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Pruritis to formulate effective R&D strategies
• Assess challenges and opportunities that influence Pruritis R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Pruritis in licensing and out licensing strategies by identifying prospective partners with progressing projects for Pruritis to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugsPlease Note: The report will be delivered in 2-3 business days upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook